Cervical intraepithelial lesion
Conditions
Interventions
treatment group (5-ALA-PDT):None
control group:None
Sponsors
The International Peace Maternity & Child Health Hospital of the China Welfare Institute
Eligibility
Sex/Gender
Female
Age
25 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Female, aged 25-45; 2) HPV positive; 3) One week after LEEP for HSIL (CIN2, CIN3), the pathological examination showed positive HSIL margins (CIN1, CIN2, CIN3), including the outer, inner, and basal margins; 4) Preoperative colposcopy evaluation images; 5) After 3 months of LEEP surgery, there was no sexual activity, and condoms were used throughout sexual activity from 3 months after LEEP surgery. 6) Willing to retain cervical structure and/or function, voluntarily participating and signing an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Preoperative cytological examination suspected the presence of cancerous lesions and infiltration; 2) Preoperative colposcopy examination showed lesions extending to the vaginal fornix and presence of vaginal wall lesions 3) Preoperative cervical pathology with cervical microfocal infiltration 4) Cervical LEEP surgery indicates cervical invasive cancer. 5) Severe pelvic inflammation, cervical inflammation, or other severe gynecological inflammation were found one week after cervical LEEP surgery 6) Individuals with undiagnosed vaginal bleeding; 7) Individuals currently suffering from allergic diseases; Suspected or known to have porphyria, or known to have a history of allergies to experimental drugs and drugs with similar chemical structures; 8) Individuals with severe cardiovascular, neurological, psychiatric, endocrine, liver function, and hematopoietic system diseases; Those who are known to have severe immune dysfunction or require long-term use of glucocorticoids and immunosuppressants; Patients with other malignant tumors; 9) Pregnant and lactating women; 10) Poor compliance, or expected inability to complete the trial and follow-up due to limitations such as place of residence; 11) In addition to the above, the researchers have determined that it is not suitable to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cervical biopsy pathology;HPV;Cervical cytology; | — |
Countries
China
Contacts
Public ContactYi Chen
The International Peace Maternity & Child Health Hospital attached to Medicine College Shanghai Jiaotong University
Outcome results
None listed